Details for Patent: 7,550,153

Title:	Pantoprazole multiparticulate formulations
Abstract:	Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose(hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose(hypromellose) and water.
Inventor(s):	Venkata Ramana Rao; Sripriya (Mahwah, NJ), Shah; Syed M. (East Hanover, NJ), Tatapudy; Hanumantharao (Suffern, NY), Saunders; Richard William (Palisades, NY), Fawzi; Mahdi (Morristown, NJ), Nagi; Arwinder (Thiells, NY), Singh; Shailesh (Bardonia, NY), Hasan; Sumon A (Monroe, NY)
Assignee:	Wyeth (Madison, NJ)
Filing Date:	Mar 30, 2007
Application Number:	11/731,474
Claims:	1. A method of treating ulcers of the stomach and duodenum, gastroesophageal reflux disease (GERD), or Zollinger-Ellison Syndrome in a mammalian subject, comprising the step of administering to the subject a plurality of pantoprazole multiparticulates, each of which comprise: a core consisting of about 45% w/w pantoprazole sodium sesquihydrate and one or more excipients comprising about 25% to 30% w/w microcrystalline cellulose, about 4% to 6% w/w polysorbate 80, about 14% to 16% w/w crospovidone, about 0.5 to 2% w/w hydroxypropyl methylcellulose, about 5% to 8% w/w sodium carbonate, and about 1 to about 2% water; an initial seal coat comprising hydroxypropylmethyl cellulose on the spheroid core; and an enteric coat on the initial coated spheroid core, wherein the multiparticulates have an average size in the range from about 0.7 mm to about 1.25 mm. 2. The method according to claim 1, wherein the mammalian subject is a human. 3. The method according to claim 1, wherein said plurality of multiparticulates comprises a pantoprazole compound present in an amount of about 40 mg of pantoprazole per 100 mg uncoated multiparticulates. 4. The method according to claim 1, wherein the multiparticulates have an average diameter of about 1 mm. 5. The method according to claim 1, wherein said enteric coat comprises a copolymer of methacrylic acid and methacrylates 6. The method according to claim 5, wherein the enteric coat comprises about 48% w/w of the coated multiparticulates. 7. The method according to claim 1, further comprising a final seal coat on the enteric coat. 8. The method according to claim 7, wherein the final seal coat comprises about 0.1 to 10 wt% of the multiparticulates. 9. The method according to claim 7, wherein the final seal coat comprises hydroxypropyl methyl cellulose (hypromellose). 10. The method according to claim 1 wherein said initial seal coat is in the range of about 2 to 4% w/w of the weight of the uncoated core. 11. The method according to claim 1, wherein the initial seal coat comprises hypromellose. 12. The method according to claim 1, wherein the spheroid tore consists essentially of: TABLE-US-00013 pantoprazole sodium sesquihydrate 45% w/w microcrystalline cellulose 27% w/w polysorbate 80 5% w/w crospovidone 15% w/w hydroxypropylmethylcellulose 1% w/w, and sodium carbonate 7% w/w. 13. The method according to claim 1, wherein the enteric coating comprises a copolymer of merhaczylic acid and methyacrylates and further comprising an outer seal coat comprising hydroxypropylmethyl cellulose and wherein the multiparticulates have an average diameter of about 1 mm. 14. The method according to claim 1, wherein the enteric coat comprises about 48% w/w of the multiparticulates. 15. The method according to claim 1, wherein the enteric coating comprises about 30% w/w of the copolymer of methacrylic acid and methacrylate, about 15% w/w talc, about 3% triethyl citrate and a pH adjuster; said amounts being by weight of the multiparticulates. 16. The method according to claim 1, wherein the multiparticulates are administered in a food. 17. The method according to claim 16 wherein the food is applesauce. 18. The method according to claim 1, wherein the multiparticulates are administered in a physiologically compatible liquid. 19. The method according to claim 1, wherein the multiparticulates are contained in a foil wrapper prior to administration. 20. The method according to claim 1, wherein the multiparticulates are administered in a capsule. 21. The method according to claim 1, wherein the spheroid core consists essentially of: TABLE-US-00014 pantoprazole sodium sesquihydrate about 45% w/w microcrystalline cellulose about 27% w/w polysorbate 80 about 5% w/w crospovidone about 15% w/w hydroxypropylmethylcellulose about 1% w/w, sodium carbonate about 6.5% w/w, and water.